Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
52 hedge funds and large institutions have $23.6M invested in Orexigen Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 8 closing their positions.
131% more capital invested
Capital invested by funds: $10.2M → $23.6M (+$13.4M)
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
31% more call options, than puts
Call options by funds: $1.79M | Put options by funds: $1.36M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 53 → 52 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.04M |
| 2 |
GL
GLG LLC
New York
|
+$878K |
| 3 |
BlackRock
New York
|
+$864K |
| 4 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$498K |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$465K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$93.2K |
| 2 |
Goldman Sachs
New York
|
-$65.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$40K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$37.8K |
| 5 |
Millennium Management
New York
|
-$28K |
OREX Hedge Fund Activity: Q1 2017 in Review
52 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q1 2017, worth a combined $23.6M — up 131% from $10.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new OREX positions and 8 closed out — a net gain of 3 holders — while 16 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.04M. The largest seller was Credit Suisse, cutting an estimated $93.2K.
- 52 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q1 2017, down from 53 in Q4 2016.
- Funds reported $23.6M of Orexigen Therapeutics, Inc. stock for Q1 2017, up 131% quarter-over-quarter.
- 11 funds opened new Orexigen Therapeutics, Inc. positions in Q1 2017 and 8 closed out, a net change of +3 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q1 2017 was Vanguard Group, an estimated $1.04M added.
- The largest Orexigen Therapeutics, Inc. seller in Q1 2017 was Credit Suisse, an estimated $93.2K sold.
Based on aggregated 13F filings for Q1 2017.